文献速递胸部肿瘤消化系统肿瘤支持与姑息治疗

血液系统与实体瘤癌症患者接种COVID-19疫苗加强针:系统综述与个体患者数据Meta分析

Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.
PubMed 文献 · Eur J Cancer · 2022-06-03

该系统综述与个体患者数据Meta分析纳入22项研究(17项用于meta分析),共849例血液系统癌症和82例实体瘤癌症患者,评估基础免疫无应答者接种加强针后的血清转换率。血液系统癌症无应答者血清转换率为44%(95%CI 36-53%),低于实体瘤癌症的80%(95%CI 69-87%);抗体滴度有意义升高与第二剂和第三剂间隔延长、年龄及癌症类型相关。

要点

  • 血液系统癌症无应答者加强针后血清转换率为44%(95%CI 36-53%),实体瘤癌症为80%(95%CI 69-87%)。
  • 第二剂与第三剂间隔延长与抗体滴度有意义升高显著相关(OR 1.02,95%CI 1.00-1.03,P≤0.05)。
  • 以血液系统癌症为参照,肺癌患者抗体滴度有意义升高的OR为16.8(95%CI 2.95-318),胃肠道癌为25.4(95%CI 5.26-492.21)。

核心结论

  • 接种COVID-19疫苗加强针可有效改善血清转换和抗体水平。
  • 血液系统癌症患者对加强针的反应一致差于实体瘤癌症患者。

研究设计与样本

  • 系统综述与个体患者数据Meta分析,检索PubMed、EMBASE、CENTRAL和medRxiv从2021年1月1日至2022年3月10日。
  • 纳入22项研究进行系统综述,其中17项用于无应答者血清转换的meta分析,共纳入849例血液系统癌症和82例实体瘤癌症患者。
  • 质量评估采用Joanna Briggs Institute Critical Appraisal checklist。

主要发现

  • 血液系统癌症无应答者血清转换率为44%(95%CI 36-53%),实体瘤癌症为80%(95%CI 69-87%)。
  • 个体患者数据meta分析发现抗体滴度有意义升高与第二剂和第三剂间隔延长相关(OR 1.02,95%CI 1.00-1.03,P≤0.05)。
  • 抗体滴度有意义升高与患者年龄相关(OR 0.960,95%CI 0.934-0.987,P≤0.05)。
  • 以血液系统癌症为参照,肺癌患者抗体滴度有意义升高的OR为16.8(95%CI 2.95-318,P≤0.05)。
  • 以血液系统癌症为参照,胃肠道癌患者抗体滴度有意义升高的OR为25.4(95%CI 5.26-492.21,P≤0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with cancer have an increased risk of severe disease and mortality from COVID-19, as the disease and antineoplastic therapy cause reduced vaccine immunogenicity. Booster doses have been proposed to enhance protection, and efficacy data are emerging from several studies. OBJECTIVE: To evaluate the proportion of COVID-19 primary vaccination non-responders with cancer who seroconvert after a booster dose. METHODS: PubMed, EMBASE, CENTRAL and medRxiv were searched from 1st January 2021 to 10th March 2022. Quality was assessed using the Joanna Briggs Institute Critical Appraisal checklist. RESULTS: After the eligibility assessment, 22 studies were included in this systematic review and 17 for meta-analysis of seroconversion in non-responders, pooling a total of 849 patients with haematological cancer and 82 patients with solid cancer. Haematological cancer non-responders exhibited lower seroconversion at 44% (95% CI 36-53%) than solid cancer at 80% (95% CI 69-87%). Individual patient data meta-analysis found the odds of having a meaningful rise in antibody titres to be significantly associated with increased duration between the second and third dose (OR 1.02, 95% CI 1.00-1.03, P ≤ 0.05), age of patient (OR 0.960, 95% CI 0.934-0.987, P ≤ 0.05) and cancer type. With patients with haematological cancer as a reference, patients with lung cancer had 16.8 times the odds of achieving a meaningful increase in antibody titres (OR 16.8, 95% CI 2.95-318, P ≤ 0.05) and gastrointestinal cancer patients had 25.4 times the odds of achieving a meaningful increase in antibody titres (OR 25.4, 95% CI 5.26-492.21, P ≤ 0.05). CONCLUSIONS: administration of a COVID-19 vaccine booster dose is effective in improving seroconversion and antibody levels. Patients with haematological cancer consistently demonstrate poorer response to booster vaccines than patients with solid cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mai AS, Lee ARYB, Tay RYK, et al. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. Eur J Cancer. 2022. PMID: 35753213. doi:10.1016/j.ejca.2022.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。